Theme: Emerging & Innovative approaches for the advancement of cancer therapy

Eurocancersummit-2015

Eurocancersummit-2015

It is our greatest pleasure to welcome you to the official website of 8th Euro Global Summit on Cancer Therapy, that aims at bringing together the professors, researchers, clinicians, educators, program developers to provide an international forum for the dissemination of original research results, new ideas and practical development experiences which concentrate on both theory and practices in our Medical meetings. The conference will be on November3-5, 2015 at Valencia, Spain. The theme of the conference is around, “Emerging and Innovative approaches for the advancement of cancer therapy. Cancer is a malignant growth or tumour resulting from an uncontrolled division of cells. Cancer is the second most common cause of death in the European Union. Cancer of the breast and lung cancers is the leading cancer types in European males and females. The burden of new cancer cases in 2010 was estimated to be around 3 millions, in European counties to 53% of this load. The burden of cancer is increasing worldwide despite advances in cancer diagnosis and treatment.  However, the worldwide cancer statistics depict that 14.1 million adults in the world were diagnosed with cancer and 1.7million deaths occurred in 2012 in Europe and 7.4 millions globally.For more informtation about the cancers please visit euorpe cancer conferenes

Cancer is the most important cause of death and morbidity in Europe after cardiovascular diseases. Cancer is in many cases avoidable, and early detection increases the chance of cure substantially. The most frequently occurring forms of the Cancer disease in the EU are colorectal, breast, prostate and lung cancers. In men, lung cancer is the most frequent cause of cancer death, while in women, it is breast cancer. In both men and women, colorectal cancer is the second most common cause of cancer death. Although significant advances are being made in the fight against the disease, cancer remains a key public health concern and a tremendous burden on European Cancer societies.

Cancer Statistics  in Europe are more than 3 million new cases and 1.7 million deaths each year, Recent Cancer conference represents the second most important cause of death and morbidity in Europe. On a global scale, cancer accounted for 7.4 million deaths (around 13% of the total) in 2004.Europe comprises only one eighth of the total world population but has around one quarter of the global total of cancer cases: some 3.2 million new patients per year and organizes cancer meetings, oncology meetings in European countries.

OMICS International is an amalgamation of Open Access publications and worldwide international science conferences and events. OMICS Cancer Conferences has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS International also organizes 1000 International conferences annually across the globe, which includes Cancer Conferences like skin cancer conference, breast cancer conference, liver cancer conference, lung cancer meetings, and oncology conferences where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions and which helps get possibilities for treating the diseases with new era, technology and research.

In addition to producing our own oncology meetings, cancer conferences, cancer meetings, oncology conferences  we cooperate with national oncology associations and institutes, cancer leagues and other local groups to ensure the highest academic standards in their programs and to stimulate continuing medical oncology education and training.

OMICS International Organizes 300+ Conferences  Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 500+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

 In Spain, there are approximately 0.8 million new cases of cancer each year. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years. Lung cancer is one of the most aggressive tumours and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer. Prostate cancer, today the most common tumour in men, has an increasingly favourable prognosis, with a global survival rate of 76%, which is higher in young adults. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.Every year omics organizes cancer meetings in europe

For more information please visit: Euro Cancer Summit Market Report

Cancer Basic and Applied Research

Cancer Cell Biology, Diagnosis and Applied Research are using cell biological and other methods to investigate the mechanisms that regulate cell proliferation and differentiation. This is an approach applied to understanding basic cell physiology, cancer biology and the pathogenesis of infectious diseases. There is different area of research within the Research Theme. There is considerable interaction between individual laboratories in those areas. Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells, the ability to give rise to all cell types found in a particular cancer sample.  The process by which cancer cells spread to other parts of the body is also called metastasis. Virtually all cancers, including cancers of the blood and the lymphatic system, can form metastatic tumors. The metastasis of blood and lymphatic system cancers to the lung, central nervous system, heart and other tissues has been reported. Cancer is a multistep process involving several cell signaling pathways. These include the capacities to proliferate independently of exogenous growth-promoting signals, to invade surrounding tissues and metastasize to distant site sand to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. Membrane proteins are involved in the prognosis of the most common forms of cancer. Membrane proteins are the hallmark of a cancer cell. These overexpressed membrane receptors are becoming increasingly important in cancer cell therapy. Molecular oncology is an interdisciplinary medical specialty at the interface of medicinal chemistry and oncology that refers to the investigation of the chemistry of cancer and tumors at the molecular scale, involved in basic and translational cancer research on the cell and tissue level and bioinformatics developments in this area, and clinical applications.  In the social sciences and life sciences, a case study is an implementation of a research method involving an up-close, and detailed examination of a subject of study (the case), as well as its related contextual conditions.

Organ-Specific, Cancer Genetics

Organ Specific Cancers are cancers named basing on the location of cancer in the body organ. Its incidence is showing an increasing trend in various parts of the earth and has been a significant public health problem despite advances in the understanding of the molecular and cellular events that underlie. This review aims to update the current related information about organ specific cancers and provide a further understanding about their diagnosis and treatment. The malignant and unrestrained division of cell is one of the features of cancer. But cancer can be numerously varied, as numerous as the different body parts. It generally owes its origin to one of the many organs of the human body, gradually affecting those around. Cancer can affect just about every organ in the human body. Each type of cancer is unique with its own causes, symptoms, and methods of treatment. Many people are surprised to learn that cancer can affect parts of the body like eyes and the heart. Lung cancer was the most common cancer worldwide in men contributing nearly 17% of the total number of new cases diagnosed in 2012. The top three, lung, prostate and colorectal cancers, contributed nearly 42% of all cancers (excluding non-melanoma skin cancer). There are more than 200 different types of cancer, but Breast cancer , Head & Neck Cancer, Blood, lung and leukemia cancer cancers that are diagnosed with the greatest frequency. Retinoblastoma  (eye cancer) which is the most frequent type of cancer affecting the eyeball in children. Anal cancer is an uncommon malignancy that starts in the anus -- the opening at the end of the rectum. The two most common types of renal cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. The leading cause of liver cancer is cirrhosis due to either hepatitis B, hepatitis C, or alcohol. Liver cancers are formed from either the liver itself or from structures within the liver, including blood vessels or the bile duct. The risk of ovarian cancer increases in people who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age or reach menopause at an older age. Cancer genetics is now one of the fastest expanding medical specialties. At the molecular level, cancer is caused by mutations in DNA, which result in aberrant cell proliferation. Most of these mutations are acquired and occur in somatic cells. However, some people inherit mutation in the germ line. The mutations occur in two classes of cellular genes: oncogenes and tumor suppressor genes.

Advances in Cancer treatment and Biomarkers

Malignancy is most familiar as a characterization of cancer. A malignant tumor contrasts with a non-cancerous benign tumor in that a malignancy is not self-limited in its growth, is capable of invading into adjacent tissues, and may be capable of spreading to distant tissues. A benign tumor has none of those properties. A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected bio fluids like blood or serum. Small molecules can penetrate the cell membrane to interact with targets inside a cell. Small molecules are usually designed to interfere with the enzymatic activity of the target protein. The majority of tumor cells have defects in maintaining genomic stability owing to the loss of an appropriate response to DNA damage. New anticancer agents are exploiting this vulnerability of cancer cells to enhance therapeutic indexes, with limited normal tissue toxicity. Due to the numerous roles of p53 in genomic stability and its defects in many human cancers, therapeutic agents that restore p53 activity in tumors are the subject of multiple clinical trials. In many cancers studied thus far, a small population of cells called cancer stem cells self-renew to replenish the growing cancer. In order to eliminate the disease, it is these cells that chemotherapy must wipe out. Current treatments destroy cancer cells indiscriminately, draining the reservoir of cancer cells without specifically eliminating the cancer's source. In cancer, protein-protein interaction form signaling nodes and hubs that transmit pathophysiological cues along molecular networks to achieve an integrated biological output, thereby promoting tumor genesis, tumor progression, invasion, and metastasis. The study of cancer epidemiology uses epidemiological methods to find the cause of cancer and to identify and develop improved treatments.

Anti-cancer drug delivery

Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Tissue-specific gene delivery using immune liposomes has also been achieved in brain, and breast cancer tissue. Antibody-directed enzyme pro drug therapy involves the application of cancer associated monoclonal antibodies which are linked to a drug-activating enzyme. Subsequent systemic administration of a non-toxic agent results in its conversion to a toxic drug, and resulting in a cytotoxic effect which can be targeted at malignant cells. A cancer vaccine is a vaccine that either treats existing cancer or prevents development of a cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines. There are currently no vaccines able to prevent all cancers. However vaccines against some oncoviruses have proven extremely effective. Treatment often fails when cancer becomes resistant to anti-cancer drugs. Thus, drug resistance is a big challenge facing the survival of cancer patients. Research in discovering and designing drugs with new chemistry structure or mechanism of action is critical to overcome the drug resistance problem and give patient better chance to survive longer. The use of nanotechnology in cancer treatment offers some exciting possibilities, including the possibility of destroying cancer tumors with minimal damage to healthy tissue and organs, as well as the detection and elimination of cancer cells before they form tumors. Genomics, particularly high-throughput sequencing and characterization of expressed human genes, has created new opportunities for drug discovery. Knowledge of all the human genes and their functions may allow effective preventive measures, and change drug research strategy and drug discovery development processes.

Novel Approaches to Cancer Therapeutics and metabolomics

Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamics marker of drug effect. There is potential for the metabolome to have a multitude of uses in oncology, including the early detection and diagnosis of cancer and as both a predictive and pharmacodynamic marker of drug effect. Despite the current optimism, a number of important limitations to the discovery of novel single tumor markers have been identified, including study design bias, and artifacts related to the collection and storage of samples. Despite the fact that new technologies and strategies often fail to identify well-established cancer biomarkers and show a bias toward the identification of high-abundance molecules, these technological advances have the capacity to revolutionize biomarker discovery. The study of the tumor metabolism, also known as tumor metabolome describes the different characteristic metabolic changes in tumor cells. The characteristic attributes of the tumor metabolome are high glycolytic enzyme activities, the expression of the pyruvate kinase isoenzyme type M2, increased channeling of glucose carbons into synthetic processes, such as nucleic acid, amino acid and phospholipid synthesis, a high rate of pyrimidine and purine de novo synthesis, a low ratio of Adenosine triphosphate and Guanosine triphosphate to Cytidine triphosphate and Uridine triphosphate, low Adenosine monophosphate levels, high glutaminolytic capacities, release of immunosuppressive substances and dependency on methionine. The emerging field of metabolomics – which attempts to profile all metabolites within a cell or biological system – is now being used to analyze cancer metabolism on a system-wide scale, painting a broad picture of the altered pathways and their interactions with each other. While a large fraction of cancer metabolomics research is focused on finding diagnostic biomarkers, metabolomics is also being used to obtain more fundamental mechanistic insight into cancer and carcinogenesis.

Advancement in Cancer Therapy:

A common misconception that most people have about cancer is that suffering from cancer is the end of life. However it is not true as with numerous advances in the diagnosis and treatment options, you can improve the quality of life and get treated (if the condition is diagnosed in early stage). With advances in chemotherapy, radiotherapy, surgery, hormonal therapies and vaccines, the current treatment options for cancer have better mechanism of action and fewer side effects. Here are some of the significant advances and research in the field of cancer treatment.

ADVANCES IN CHEMOTHERAPY: Currently, combination chemotherapy is a standard treatment used for various types of cancer. It is known to be one of the key reasons for increasing survival and remission rates in cancer treatment. Here’s what to expect at your first chemotherapy session. Molecular target agents in the normal body cells divide unnaturally, when a cancer forms and certain ‘factors’ or ‘cellular agents’ or even changes in normal ‘genes’ stimulate this growth of cancer. Recent advances in technology have enabled us to identify such ‘agents’ in different cancers. ADVANCES IN RADIATION THERAPY  in the field of radiation therapy – 3D conformal radiation therapy, stereotactic radiosurgery, and brachytherapy (radioactive seeds), which are designed to deliver high doses of radiation to tumors while minimizing the doses delivered to nearby healthy tissue.  Stereotactic body radiation treatment (SBRT): Also known as stereotactic ablative radiation therapy, SBRT appears to be a very useful new approach for many otherwise difficult to treat cancers such as in the lung. This technique uses various angles to treat the tumor. In this technique the tumor is imaged and the robotic arm is adjusted to directly attack the cancer and not the normal tissue.

Cancer immunobiology, immunotherapy and Stem Cell Therapy

Experimental cancer treatments are medical therapies intended or claimed to treat cancer by improving on, supplementing or replacing conventional methods (surgery, chemotherapy, radiation, and immunotherapy). Oncolytic Virotherapy is an exciting, increasingly recognized discipline in cancer research. The recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Although cancer has historically been considered immunologically silent, several preclinical and clinical studies suggest that immunotherapy has the potential to improve clinical outcomes for patients with breast cancer. Overall, immunotherapy holds several key advantages over conventional chemotherapeutic and targeted treatments directed at the tumor itself. The common types of immunotherapy include Monoclonal antibodies, Cancer vaccines and Non-specific immunotherapies. One common type of cancer immunotherapy drug for breast cancer is Herceptin. This drug binds with specific proteins on breast cancer cells to slow or stop their growth. Your care team may recommend Herceptin to target breast tumors that produce too much of (or overexpress) a protein called HER2, which can also signal more aggressive cancers. Immunotherapy is a promising treatment for breast cancer, including advanced and recurrent forms of the disease. Immunotherapy may be used alone or in conjunction with other cancer treatments, such as radiation therapy and chemotherapy. Radiation therapy is treatment with high-energy rays or particles that destroy cancer cells. Radiation to the breast is often given after breast-conserving surgery to help lower the chance that the cancer will come back in the breast or nearby lymph nodes. Radiation may also be recommended after mastectomy in patients either with a cancer larger than 5 cm, or when cancer is found in the lymph nodes. Stem cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem cell therapy, but some therapies derived from umbilical cord blood are also in use.

 

 

 

Cancer is the most important cause of death and morbidity in Europe after cardiovascular diseases. Cancer is in many cases avoidable, and early detection increases the chance of cure substantially. The most frequently occurring forms of the Cancer disease in the EU are colorectal, breast, prostate and lung cancers. In men, lung cancer is the most frequent cause of cancer death, while in women, it is breast cancer. In both men and women, colorectal cancer is the second most common cause of cancer death. Although significant advances are being made in the fight against the disease, cancer remains a key public health concern and a tremendous burden on European Cancer societies.

Cancer Statistics  in Europe are more than 3 million new cases and 1.7 million deaths each year, Recent Cancer conference represents the second most important cause of death and morbidity in Europe. On a global scale, cancer accounted for 7.4 million deaths (around 13% of the total) in 2004.Europe comprises only one eighth of the total world population but has around one quarter of the global total of cancer cases: some 3.2 million new patients per year and organizes cancer meetings, oncology meetings in European countries.

OMICS International is an amalgamation of Open Access publications and worldwide international science conferences and events. OMICS Cancer Conferences has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS International also organizes 1000 International conferences annually across the globe, which includes Cancer Conferences like skin cancer conference, breast cancer conference, liver cancer conference, lung cancer meetings, and oncology conferences where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions and which helps get possibilities for treating the diseases with new era, technology and research.

In addition to producing our own oncology meetings, cancer conferences, cancer meetings, oncology conferences  we cooperate with national oncology associations and institutes, cancer leagues and other local groups to ensure the highest academic standards in their programs and to stimulate continuing medical oncology education and training.

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 03-05, 2015
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View